GlassScriptPhysician profile
Kung-Ming Jan
NPI 1699752261
$6,513.12
in general payments reported to CMS, 2019-2025
36 companies · $799 in 2025
The $799 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,225 · 2020: $674 · 2021: $1,289 · 2022: $1,063 · 2023: $927 · 2024: $535 · 2025: $799.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,202 · Education: $58.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,202.39 |
| Education | $58.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,338.02 | 2019-2025 | Jardiance, Cyltezo, Spiriva Respimat |
| Janssen Pharmaceuticals, INC | $510.77 | 2019-2022 | |
| Pfizer INC. | $456.87 | 2019-2025 | |
| Boston Scientific Corporation | $427.91 | 2019-2023 | Watchman Flx |
| Novo Nordisk INC | $427.85 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Novartis Pharmaceuticals Corporation | $416.83 | 2019-2025 | |
| Amgen INC. | $371.69 | 2019-2023 | Repatha |
| Glaxosmithkline, LLC. | $290.92 | 2019-2023 | Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $285.72 | 2021-2023 | Verquvo |
| Actelion Pharmaceuticals US, INC. | $279.39 | 2019-2023 | Opsumit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $264.85 | 2019-2022 | |
| Alnylam Pharmaceuticals INC. | $193.25 | 2025 | Amvuttra |
| E.R. Squibb & Sons, L.L.C. | $117.52 | 2019-2022 | |
| Janssen Biotech, INC. | $111.25 | 2022-2025 | Stelara, Tremfya |
| Sanofi-Aventis U.S. LLC | $103.73 | 2019-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $94.15 | 2022-2024 | Farxiga, Lynparza |
| Kiniksa Pharmaceuticals International, Plc | $84.89 | 2024 | Arcalyst |
| Redhill Biopharma INC. | $78.92 | 2021 | |
| Amarin Pharma, INC. | $75.34 | 2019-2021 | |
| Lexicon Pharmaceuticals, INC. | $72.23 | 2023 | Inpefa |
| Aimmune Therapeutics, INC. | $67.32 | 2025 | Vowst |
| Intercept Pharmaceuticals, INC. | $62.58 | 2020-2024 | |
| Celltrion USA INC. | $58.61 | 2024 | Zymfentra |
| Ardelyx, INC. | $55.77 | 2024-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $40.84 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $39.66 | 2024 | |
| Kiniksa Pharmaceuticals, LTD. | $33.16 | 2023 | Arcalyst |
| Lilly USA, LLC | $25.39 | 2023 | Mounjaro |
| Arbor Pharmaceuticals, INC. | $21.63 | 2021 | |
| Genzyme Corporation | $17.14 | 2021 | |
| Optinose US, INC. | $16.33 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $16.01 | 2019 | |
| Ironwood Pharmaceuticals, INC | $15.22 | 2020 | |
| Mylan Specialty L.P. | $14.53 | 2019 | |
| Electromed, INC. | $13.92 | 2021 | |
| Insmed, INC. | $12.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kung-Ming Jan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.